Literature DB >> 9033652

Multiple types of aberrations in the p16 (INK4a) and the p15(INK4b) genes in 30 esophageal squamous-cell-carcinoma cell lines.

H Tanaka1, Y Shimada, M Imamura, I Shibagaki, K Ishizaki.   

Abstract

To determine the role and mode of inactivation of the p16 and p15 genes in human esophageal tumors, we examined alterations and expression of the alpha and beta forms of the p16 gene, 5' CpG island methylation of p16 exon 1 alpha, and alterations of the p15 gene in 30 esophageal squamous-cell-carcinoma cell lines. Of 30 such cell lines examined, 28 (93%) showed aberrations of the alpha form of the p16 gene: 18 homozygous deletions, 6 point mutations and 4 hypermethylation. Methylation was exclusively observed in cell lines with the wild-type alpha form. Of the 6 point mutations, one was observed in exon 1 alpha, one in the splice acceptor site of intron 1 and the remaining 4 were in exon 2. In the beta form, 18 homozygous deletions and 3 point mutations in exon 2 were detected, but no point mutation was found in exon 1 beta. All mutations in exon 2 gave rise to premature termination codons in the reading frame of the alpha transcript, while no non-sense mutations were observed in the reading frame of the beta transcript. Among 12 cell lines without homozygous deletions of the alpha and beta forms of the p16 gene, the expected wild-type beta transcript was observed in 8 cell lines, whereas only one cell line expressed the expected wild-type alpha transcript. Homozygous deletions of the p15 gene were observed in 16 cell lines (53%), and no point mutations were detected. Twelve cell lines had alterations only in the alpha form of the p16 gene, while none showed aberrations exclusively in the p15 gene. Taken together, these results indicate that inactivation of the beta form of the p16 gene and the p15 gene are not so frequent as that of the alpha form of the p16 gene in ESC cell lines, suggesting that aberration of the alpha form of p16 gene is the primary target of 9p loss in ESC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9033652     DOI: 10.1002/(sici)1097-0215(19970207)70:4<437::aid-ijc11>3.0.co;2-c

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Mechanisms for nicotine in the development and progression of gastrointestinal cancers.

Authors:  Kendal Jensen; Syeda Afroze; Md Kamruzzaman Munshi; Micheleine Guerrier; Shannon S Glaser
Journal:  Transl Gastrointest Cancer       Date:  2012-04

2.  The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53.

Authors:  K D Robertson; P A Jones
Journal:  Mol Cell Biol       Date:  1998-11       Impact factor: 4.272

3.  Downregulation of retinoic acid receptor-beta(2) expression is linked to aberrant methylation in esophageal squamous cell carcinoma cell lines.

Authors:  Zhong-Min Liu; Fang Ding; Ming-Zhou Guo; Li-Yong Zhang; Min Wu; Zhi-Hua Liu
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

4.  Analysis of p16 expression and allelic imbalance / loss of heterozygosity of 9p21 in cutaneous squamous cell carcinomas.

Authors:  Sarah E Gray; Elaine Kay; Mary Leader; M Mabruk
Journal:  J Cell Mol Med       Date:  2006 Jul-Sep       Impact factor: 5.310

5.  Down-regulation of LAPTM5 in human cancer cells.

Authors:  Michelle Nuylan; Tatsuyuki Kawano; Johji Inazawa; Jun Inoue
Journal:  Oncotarget       Date:  2016-05-10

6.  Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?

Authors:  Eri Banno; Yosuke Togashi; Yu Nakamura; Masato Chiba; Yoshihisa Kobayashi; Hidetoshi Hayashi; Masato Terashima; Marco A de Velasco; Kazuko Sakai; Yoshihiko Fujita; Tetsuya Mitsudomi; Kazuto Nishio
Journal:  Cancer Sci       Date:  2016-07-14       Impact factor: 6.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.